Lucid Diagnostics (LUCD) IPO: 7 Things to Know

Lucid Diagnostics (NASDAQ: LUCD), which produces diagnostic tests for esophageal precancer and cancer, is scheduled to go public next week. Here are 7 key things to know about the upcoming LUCD IPO.

1. Lucid Diagnostics IPO Date - Lucid Diagnostics is due to go public on October 14, 2021. Lucid Diagnostics will start trading under the ticker symbol “LUCD” on the Nasdaq stock exchange. Generally, shares that make their public stock market debuts start trading between 10 AM - 2 PM ET.

2. Lucid Diagnostics IPO Pricing - LUCD is expected to price its shares between $14.00 and $16.00.

3. Shares Offered - Lucid Diagnostics is looking to sell 5,000,000 shares of its common stock. The S-1 filing shows the number of outstanding shares after IPO offering would be 36,992,077 shares.

4. LUCD IPO Valuation - Lucid Diagnostics is seeking a valuation of between $517.9 million and $591.8 million.

5. LUCD IPO Raised Proceeds: At the midpoint of the pricing range, Lucid Diagnostics is looking to raise $75 million. The company plans to use the raised proceeds to expand sales infrastructure, optimize the pilot launch of new products, complete ongoing clinical trials, and expand manufacturing capacities.

6. LUCD IPO Underwriters - Cantor and Canaccord Genuity are joint bookrunners. BTIG and Needham & Company are co-lead managers.

7. LUCD Financials - The company reported a loss of $9.8 million for the first half of the year. LUCD said in the filing it expects to “continue to incur operating losses for the foreseeable future.”

You May Also Be Interested In

• Needham Starts Kodiak AI (KDK) at Buy
• Needham Reiterates Buy Rating on Braze Inc (BRZE)
• Formation Metals Extends A-Zone 200 Metres to the South and Identifies a New Vein Set, Returning 2.53 g/t Au over 11.8 Metres and 1.41 g/t Au over 20.6 Metres at the Advanced N2 Property